TRAVOPROST

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H35F3O6
Molecular Weight	500.5477
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC2=CC(=CC=C2)C(F)(F)F

InChI

InChIKey=MKPLKVHSHYCHOC-AHTXBMBWSA-N

InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00287doi: 10.1080/00480169.1974.34145
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/12490597 | https://www.ncbi.nlm.nih.gov/pubmed/8921038

(+)-Fluprostenol is the optically active enantiomer of fluprostenol. It is a potent and highly selective prostaglandin F2-alpha (FP) receptor agonist. (+)-Fluprostenol corrected corpora lutea persistence in the mares without significant clinical side effects. It was also an effective at inducing parturition in alpacas.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostanoid FP receptor 21 Target ID: CHEMBL1987 Sources: http://www.drugbank.ca/drugs/DB00287 \| http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_LBL.pdf	Agonist 2678		1.4 nM [EC50]
Prostanoid FP receptor 21 Target ID: CHEMBL1987 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12556403 \| https://www.ncbi.nlm.nih.gov/pubmed/12490597	Agonist 2678		49.9 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Open-angle glaucoma 51 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_LBL.pdf	Primary	Approved 8429	TRAVATAN Z Approved Use TRAVATAN Z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Launch Date 2006
Infertility 14 Sources: DOI: 10.1080/00480169.1974.34145 https://www.ncbi.nlm.nih.gov/pubmed/6911921	Primary	Preclinical	Unknown Approved Use Unknown
Labor delay 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8921038	Preventing	Preclinical	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
0.018 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021994lbl.pdf	1 drop 1 times / day multiple, ocular dose: 1 drop route of administration: Ocular experiment type: MULTIPLE co-administered:		FLUPROSTENOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
0.049 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28437175	1 drop 1 times / day multiple, ocular dose: 1 drop route of administration: Ocular experiment type: MULTIPLE co-administered:		FLUPROSTENOL plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
0.039 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28437175	1 drop 1 times / day multiple, ocular dose: 1 drop route of administration: Ocular experiment type: MULTIPLE co-administered:		FLUPROSTENOL plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
45 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021994lbl.pdf	1 drop 1 times / day multiple, ocular dose: 1 drop route of administration: Ocular experiment type: MULTIPLE co-administered:		FLUPROSTENOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
31.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28437175	1 drop 1 times / day multiple, ocular dose: 1 drop route of administration: Ocular experiment type: MULTIPLE co-administered:		FLUPROSTENOL plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
20% REVIEW https://www.ema.europa.eu/en/documents/scientific-discussion/travatan-epar-scientific-discussion_en.pdf			FLUPROSTENOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.004 % 1 times / 15 min multiple, ophthalmic Overdose Dose: 0.004 %, 1 times / 15 min Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / 15 min Sources: https://pubmed.ncbi.nlm.nih.gov/25259759	unhealthy n = 1 Health Status: unhealthy Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25259759	Disc. AE: Abdominal cramps, Bleeding menstrual heavy... AEs leading to discontinuation/dose reduction: Abdominal cramps (severe, 1 patient) Bleeding menstrual heavy (severe, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25259759
0.004 % 1 times / day multiple, ophthalmic Recommended Dose: 0.004 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21257lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21257lbl.pdf	Disc. AE: Conjunctival hyperemia... AEs leading to discontinuation/dose reduction: Conjunctival hyperemia (3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21257lbl.pdf
0.004 % 1 times / day multiple, ophthalmic Recommended Dose: 0.004 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf	unhealthy n = 336 Health Status: unhealthy Population Size: 336 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf	Disc. AE: Hyperemia eye, Iritis... AEs leading to discontinuation/dose reduction: Hyperemia eye (2 patients) Iritis (1 patient) Dermatitis (1 patient) Upper respiratory infection (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf

AEs

AE	Significance	Dose	Population
Abdominal cramps	severe, 1 patient Disc. AE	0.004 % 1 times / 15 min multiple, ophthalmic Overdose Dose: 0.004 %, 1 times / 15 min Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / 15 min Sources: https://pubmed.ncbi.nlm.nih.gov/25259759	unhealthy n = 1 Health Status: unhealthy Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25259759
Bleeding menstrual heavy	severe, 1 patient Disc. AE	0.004 % 1 times / 15 min multiple, ophthalmic Overdose Dose: 0.004 %, 1 times / 15 min Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / 15 min Sources: https://pubmed.ncbi.nlm.nih.gov/25259759	unhealthy n = 1 Health Status: unhealthy Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25259759
Conjunctival hyperemia	3% Disc. AE	0.004 % 1 times / day multiple, ophthalmic Recommended Dose: 0.004 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21257lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21257lbl.pdf
Dermatitis	1 patient Disc. AE	0.004 % 1 times / day multiple, ophthalmic Recommended Dose: 0.004 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf	unhealthy n = 336 Health Status: unhealthy Population Size: 336 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf
Iritis	1 patient Disc. AE	0.004 % 1 times / day multiple, ophthalmic Recommended Dose: 0.004 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf	unhealthy n = 336 Health Status: unhealthy Population Size: 336 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf
Upper respiratory infection	1 patient Disc. AE	0.004 % 1 times / day multiple, ophthalmic Recommended Dose: 0.004 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf	unhealthy n = 336 Health Status: unhealthy Population Size: 336 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf
Hyperemia eye	2 patients Disc. AE	0.004 % 1 times / day multiple, ophthalmic Recommended Dose: 0.004 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.004 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf	unhealthy n = 336 Health Status: unhealthy Population Size: 336 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	esterase 72

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
esterase 72	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21257_Travatan_biopharmr.pdf#page=10	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:746859	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:746859
ChemicalBook	CB5703458	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5703458
MolPort	MolPort-006-167-507	https://www.molport.com/shop/molecule-link/MolPort-006-167-507
ZINC	ZINC000004474682	http://zinc15.docking.org/substances/ZINC000004474682
eMolecules	26757104	https://www.emolecules.com/cgi-bin/more?vid=26757104

PubMed

Title	Date	PubMed
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.	2000 Jan 17	10634944
Prostanoids for the management of glaucoma.	2008 Nov	18983226

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® (travoprost ophthalmic solution) should not be administered more than once daily

Route of Administration: Topical

In Vitro Use Guide

Travoprost stimulated the contraction of isolated non-pregnant female rat uterus in a concentration-dependent manner with the agonist potency EC(50)=1.3+/-0.07 nM

Name

Type

Language

TRAVOPROST

Official Name

English

travoprost [INN]

Common Name

English

TRAVOPROST [JAN]

Common Name

English

TRAVOPROST [ORANGE BOOK]

Common Name

English

TRAVOPROST [USP MONOGRAPH]

Common Name

English

TRAVATAN

Brand Name

English

NSC-760366

Code

English

ISOPROPYL (Z)-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-((1E,3R)-3-HYDROXY-4-((.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)OXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOATE

Systematic Name

English

IZBA

Brand Name

English

TRAVOPROST [MART.]

Common Name

English

(1R-(1.ALPHA.(Z),2.BETA.(1E,3R*),3.ALPHA.,5.ALPHA.))-7-(3,5-DIHYDROXY-2-(3-HYDROXY-4-(3-(TRIFLUOROMETHYL)PHENOXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOIC ACID, 1-METHYLETHYL ESTER

Common Name

English

TRAVOPROST [VANDF]

Common Name

English

TRAVOPROST COMPONENT OF DUOTRAV

Brand Name

English

TRAVOPROST [USAN]

Common Name

English

Travoprost [WHO-DD]

Common Name

English

TRAVOPROST [MI]

Common Name

English

AL-6221

Code

English

OTX-TP

Common Name

English

DUOTRAV COMPONENT TRAVOPROST

Brand Name

English

TRAVOPROST [USP-RS]

Common Name

English

TRAVOPROST [EMA EPAR]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175454